Encompass Health (NYSE:EHC – Get Free Report) had its price target raised by investment analysts at Truist Financial from $100.00 to $104.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective points to a potential upside of 17.38% from the stock’s current price.
Several other analysts have also issued reports on EHC. SVB Leerink initiated coverage on shares of Encompass Health in a report on Wednesday, July 10th. They issued an “outperform” rating and a $100.00 price objective on the stock. UBS Group lifted their target price on Encompass Health from $96.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Raymond James reaffirmed a “strong-buy” rating and issued a $95.00 target price (up from $85.00) on shares of Encompass Health in a research report on Friday, April 26th. Stephens reaffirmed an “overweight” rating and issued a $105.00 target price on shares of Encompass Health in a research report on Tuesday, August 6th. Finally, Royal Bank of Canada lifted their target price on Encompass Health from $83.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, May 22nd. Nine investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $100.38.
Check Out Our Latest Report on EHC
Encompass Health Stock Down 0.8 %
NYSE EHC opened at $88.60 on Thursday. Encompass Health has a 52 week low of $57.55 and a 52 week high of $94.38. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.14. The business’s fifty day simple moving average is $86.77 and its 200-day simple moving average is $82.09. The firm has a market cap of $8.92 billion, a PE ratio of 23.95, a P/E/G ratio of 1.45 and a beta of 0.89.
Encompass Health (NYSE:EHC – Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.10. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.30 billion. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. Encompass Health’s revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.95 EPS. As a group, equities analysts anticipate that Encompass Health will post 4.09 earnings per share for the current year.
Insider Transactions at Encompass Health
In other news, CFO Douglas E. Coltharp sold 12,260 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total transaction of $1,058,528.40. Following the completion of the transaction, the chief financial officer now directly owns 136,227 shares of the company’s stock, valued at $11,761,839.18. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CFO Douglas E. Coltharp sold 12,260 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total transaction of $1,058,528.40. Following the completion of the sale, the chief financial officer now owns 136,227 shares in the company, valued at $11,761,839.18. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Elissa Joy Charbonneau sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $85.02, for a total value of $850,200.00. Following the sale, the insider now owns 18,594 shares of the company’s stock, valued at approximately $1,580,861.88. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.
Institutional Investors Weigh In On Encompass Health
Several institutional investors have recently added to or reduced their stakes in the business. Quarry LP lifted its stake in Encompass Health by 265.9% during the second quarter. Quarry LP now owns 900 shares of the company’s stock worth $77,000 after purchasing an additional 654 shares during the last quarter. Creative Planning lifted its stake in Encompass Health by 5.5% in the second quarter. Creative Planning now owns 18,343 shares of the company’s stock valued at $1,574,000 after buying an additional 962 shares during the last quarter. Algert Global LLC lifted its stake in Encompass Health by 203.2% in the second quarter. Algert Global LLC now owns 79,438 shares of the company’s stock valued at $6,815,000 after buying an additional 53,238 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Encompass Health in the second quarter valued at approximately $971,000. Finally, Dark Forest Capital Management LP purchased a new stake in Encompass Health in the second quarter valued at approximately $283,000. Hedge funds and other institutional investors own 97.25% of the company’s stock.
About Encompass Health
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Further Reading
Receive News & Ratings for Encompass Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Encompass Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
